Magnesium L-Threonate & College Athletes

Current research status for the original UCLA MgT trial, with registered outcomes and the historical AMSSM 2026 presentation.

AMSSM 35th Annual Meeting · Seattle, WA · April 23–29, 2026

Current research status

Registry source check: October 12, 2026. NCT07015047 lists the trial as active, not recruiting. The record was last updated October 15, 2025 and still gives estimated completion dates. No results are posted in the registry.

Actual study completion: final completion and follow-up dates have not yet been reconciled for this update. The registry check date is not a study-team attestation that data collection or follow-up is complete.

Masking: the 2025 biomedical protocol describes participant and investigator blinding, while the registry lists participant-only masking. The exact approved protocol version, implemented masking roles, and unblinding timing remain to be reconciled. Neither description alone establishes how masking was maintained during the trial.

Analysis status: source records, analysis populations, outcome timing, and the final analysis specification remain under review. The primary registered outcomes are deep-sleep duration and heart rate variability (HRV). Reaction time is secondary. This page does not yet report verified final trial estimates.

Study Overview

The protocol for this single-site, randomized, placebo-controlled trial describes 1 g of magnesium L-threonate (MgT) compound or rice-flour placebo nightly for four weeks in UCLA varsity athletes, with WHOOP monitoring and pre/post performance testing. The registered primary outcomes are deep sleep duration and heart rate variability (HRV), from baseline to Week 4. Reaction-time performance is a registered secondary outcome. Source records and the final analysis specification are being reconciled.

Ethics & registration: Approved by the UCLA Institutional Review Board; all participants provided informed consent. Registered on ClinicalTrials.gov as NCT07015047.
Design
Randomized Controlled Trial
Masking
Source descriptions differ
Analysis Population
Verification in progress
Duration
4 Weeks

Registered outcomes: final estimates pending

Current status checked October 12, 2026. Both primary outcomes remain visible while the source records and analysis are reconciled.

Registered Primary Outcome
Pending
Deep-sleep duration
Baseline to Week 4; final estimate and population under review
Registered Primary Outcome
Pending
Heart rate variability
Baseline to Week 4; final estimate and population under review

Interpretation

Reaction time, jump height, grip strength, and subjective sleep quality are registered secondary outcomes. Final estimates, population counts, and multiplicity-adjusted interpretations require verification. Earlier numerical analyses do not establish a treatment benefit or a final null conclusion.

Historical provisional analyses, not final trial results

These earlier web figures are preserved for context. Their analysis dates and source derivations remain unverified. The earlier reported samples were 75 for deep sleep and 107 for paired reaction time; final analysis populations remain under review.

Historical Provisional Analysis
+0.7 min
Deep and slow-wave sleep at Week 4
MgT vs placebo · 95% CI −6.0 to 7.3 · p = .844 · n = 75

Earlier analysis, n = 75. Analysis date unverified; source and analysis verification pending.

Historical Provisional Analysis
52.3 ms
Greater reduction in RIW Challenge response latency
Earlier analysis, n = 107 paired; analysis date unverified. MgT vs placebo · 95% CI 22.7 to 81.9 · p < .001
Historical Provisional Analysis
34.2 ms
Greater reduction in Speed Tap response latency
Earlier analysis, n = 107 paired; analysis date unverified. MgT vs placebo · 95% CI 8.2 to 60.2 · p = .010

The AMSSM 2026 poster presents an earlier preliminary analysis. Its findings are historical conference reports, not final verified trial estimates.

Preliminary AMSSM 2026 poster findings

These earlier figures are retained for historical context. Both the poster findings and the other historical provisional analyses require reconciliation before final conclusions can be reported. The poster reports 107 participants overall; endpoint and subgroup denominators are not fully specified.

Historical AMSSM 2026 · Reaction Time
−52.3 ms
Faster Cognitive Reaction Time
Preliminary; n = 107 as reported in the poster. MgT vs. placebo · p = 0.001
Historical AMSSM 2026 · Sleep Quantity
+54.6 min
Total Sleep Time (Week 2)
Preliminary; endpoint/subgroup n unverified. p = 0.002
Historical AMSSM 2026 · Sleep Quantity
+45.5 min
Total Sleep Time (Week 4)
Preliminary; endpoint/subgroup n unverified. p = 0.006
Historical AMSSM 2026 · Sleep Quality
+6.27 pts
WHOOP Sleep Score (Week 2)
Preliminary; endpoint/subgroup n unverified. p = 0.010
Historical AMSSM 2026 · Endurance Subgroup
+0.83 pts
Subjective Sleep Quality (Week 3)
Preliminary; endpoint/subgroup n unverified. p = 0.030
Historical AMSSM 2026 · Endurance Subgroup
−1.15 pts
DOMS / Muscle Soreness (Week 4)
Preliminary; endpoint/subgroup n unverified. p = 0.041
Historical AMSSM 2026 · High Adherence (≥90%)
−1.44 pts
Greater Soreness Reduction
Preliminary; endpoint/subgroup n unverified. p = 0.029

Download the Preliminary AMSSM 2026 Poster

PDF · 1.6 MB · Presented April 2026, Seattle, WA

Archive note, October 12, 2026: this original preliminary poster is preserved unchanged. It is not a verified final result. Read the current research status.

Attribution correction: the original poster misspells coauthor Brian Donohoe's surname.

Study support: the historical poster acknowledges WHOOP for wearable technology and statistical support. This acknowledgment does not establish all current funding or author relationships.

Download Preliminary Poster

Inclusion Criteria

  • Age 18–35 years
  • Current UCLA varsity athlete (any sport)
  • Actively training or competing during the study period
  • Willing to wear a WHOOP strap continuously for 4 weeks
  • Willing to ingest a nightly capsule for 4 weeks
  • Able to provide informed consent and comply with study procedures

Exclusion Criteria

  • Current use of magnesium supplements or investigational drugs
  • Use of prescription or over-the-counter sleep medications
  • Diagnosed sleep disorder (e.g., insomnia, sleep apnea)
  • Major medical condition limiting training or participation
  • Pregnancy or breastfeeding
  • Known history of chronic kidney or liver disease
  • Allergy or intolerance to magnesium
  • Inability to comply with study procedures

Outcome Measures

Primary Outcomes

Deep Sleep Duration
Slow-wave sleep measured nightly via WHOOP; weekly averages compared
Baseline → Week 4
Heart Rate Variability (HRV)
Nightly HRV (ms) via WHOOP; weekly averages for autonomic recovery
Baseline → Week 4

Secondary Outcomes

Countermovement Jump Height
Jump height assessed using force plate technology
Baseline & Week 4
Reaction Time
Standardized light-based test (BlazePod)
Baseline & Week 4
Handgrip Strength
Calibrated dynamometer; average of 3 trials on dominant hand
Baseline & Week 4
Subjective Sleep Quality
Single-Item Sleep Quality Scale (0–10) daily via REDCap
Daily for 4 weeks

Investigators

Kimberly Burbank, MD
Presenting Author · AMSSM 2026
UCLA Faculty · Principal Investigator
Jeremy Swisher, MD
Principal Investigator
UCLA · David Geffen School of Medicine
Joshua Goldman, MD, MBA
Principal Investigator
UCLA · David Geffen School of Medicine
Brian Donohoe, MD
Co-Investigator
UCLA · David Geffen School of Medicine
Calvin Duffaut, MD
Co-Investigator
UCLA · David Geffen School of Medicine
Nelson Boland, MD
Co-Investigator
UCLA · David Geffen School of Medicine
Nicolas Hatamiya, DO
Collaborating Investigator
UCSF · Department of Orthopaedic Surgery
Jeremy Vail, PT, SCS, OCS
Co-Investigator
UCLA Athletics

References

Key peer-reviewed literature supporting the rationale and design of this pilot study.

  1. The Role of Magnesium in Sleep Health: A Systematic Review of Available Literature Arab A, Rafie N, Amani R, Shirani F. Biological Trace Element Research. 2023;201(1):121–128. PMID: 35184264
  2. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial Hausenblas HA, Lynch T, Hooper S, Shrestha A, Rosendale D, Gu J. Sleep Medicine: X. 2024;8:100121. PMID: 39252819
  3. The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial Lopresti AL, Smith SJ. Frontiers in Nutrition. 2026. PMID: 41601871
  4. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial Schuster J, Cycelskij I, Lopresti A, Hahn A. Nature and Science of Sleep. 2025. PMID: 40918053
  5. Enhancement of Learning and Memory by Elevating Brain Magnesium Slutsky I, Abumaria N, Wu LJ, et al. Neuron. 2010;65(2):165–177. PMID: 20152124
  6. Sleep and Athletic Performance: The Effects of Sleep Loss on Exercise Performance, and Physiological and Cognitive Responses to Exercise Fullagar HHK, Skorski S, Duffield R, et al. Sports Medicine. 2015;45(2):161–186. PMID: 25315456
  7. A Validation of Six Wearable Devices for Estimating Sleep, Heart Rate and Heart Rate Variability in Healthy Adults Miller DJ, Sargent C, Roach GD. Sensors. 2022;22(16):6317. PMID: 36016077

View on ClinicalTrials.gov

Access the full study record, protocol details, and enrollment status.

NCT07015047

Want to get involved?

UCLA varsity athletes can join an active study, and researchers or partners can collaborate with the HERO Lab.

Back to Publications